A Phase 1b, Open Label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors
Latest Information Update: 11 Feb 2021
At a glance
- Drugs Efineptakin alfa (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Genexine
- 21 May 2020 According to an I-MAB Biopharma media release, The restoring ability of T cell deficiency of TJ107/HyLeukin-7™ in a Phase 1b study (NCT03478995) by Genexine was presented at the Society for Immunotherapy of Cancer's 34th Annual Meeting in 2019.
- 07 May 2020 Status changed from recruiting to completed.
- 05 Nov 2018 Planned number of patients changed from 42 to 45.